March 31, 2017
Albuquerque, NM, March 31, 2017. Agilvax, Inc., a biotechnology company that is developing novel cancer stem cell targeting immunotherapies, announced today that Dr. John O’Rourke, Director of Oncology, will be presenting a poster, AX09: An Immunotherapy Candidate Targeting the Breast Cancer Stem Cell Protein xCT, at the American Association for Cancer Research (AACR) Annual Meeting to be held in Washington, DC, April 1-5, 2017. Additionally, Agilvax’s key collaborator, Dr. Federica Cavallo, from the University of Turin will be presenting data during her presentation, The cystine/glutamate antitporter (xCT): A new cancer stem cell target for anticancer vaccines.
|Session Title:||Enzymes and Hormones and Metabolism in Tumor Immunity|
|Date and Time:||Wednesday Apr 5, 2017 8:00 AM - 12:00 PM|
|Location:||Convention Center, Halls A-C, Poster Section 24|
|Poster Board No:||4|
|Poster Title:||AX09: An Immunotherapy Candidate Targeting the Breast Cancer Stem Cell Protein xCT|
|Session Type:||Recent Advances in Prevention Research|
|Session Title:||Premalignant Lesions as Targets for Immunoprevention|
|Session Start Time:||Tuesday, April 4, 2017, 1:00 PM|
|Session End Time:||Tuesday, April 4, 2017, 2:45 PM|
|Location:||Ballroom C, Level 3, Washington Convention Center|
|CME Status:||CME-Designated Session|
|Presentation Title:||The cystine/glutamate antiporter (xCT): A new cancer stem cell target for anticancer vaccines|
Agilvax (www.agilvax.com) is a biotechnology company that develops innovative cancer therapeutics and vaccines using its proven virus-like particle (VLP) platform technology. Agilvax’s lead immunotherapy product, AX09, is intended for the treatment of triple-negative breast cancer (TNBC). The Company is also developing vaccines against infectious diseases with a high unmet clinical need, such as respiratory syncytial virus (RSV). Agilvax has a solid intellectual property portfolio covering products (composition of matter and method of use) and the discovery platform. The Company was formed in 2011 and has raised just over $4 million in equity investment (Series A). The Company has also secured collaborations with government (NIH) and several pharmaceutical partners (Leidos, Integrated Biotherapeutics, Humabs Biomed). Agilvax is headquartered in Albuquerque, NM with offices in El Paso, TX.